Severe Ocular Myositis after Ipilimumab Treatment for Melanoma: A Report of 2 Cases

Journal of Immunotherapy

Volumn 40, Issue 7, 2017, Pages 282-285

  Pushkarevskaya, Anna ^a   Neuberger, Ulf ^a   Dimitrakopoulou Strauss, Antonia ^b   Enk, Alexander ^a   Hassel, Jessica C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

immune related adverse events; intravenous immunoglobulin; Key Words: ipilimumab; melanoma; ocular myositis

Indexed keywords

FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN; IPILIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; STEROID; VEMURAFENIB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BLOOD ANALYSIS; BRAIN METASTASIS; CANCER SURGERY; CASE REPORT; CHEMOSIS; CLINICAL ARTICLE; DIZZINESS; DRUG WITHDRAWAL; EYE BURNING; EYE PAIN; FEMALE; GAMMA KNIFE RADIOSURGERY; HEADACHE; HUMAN; HYPOPHYSITIS; LUNG METASTASIS; LUNG RESECTION; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYOSITIS; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR MYOSITIS; OPHTHALMOPLEGIA; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PTOSIS; RASH; THYROIDITIS; COMPLICATION; MELANOMA; MULTIMODALITY CANCER THERAPY; ORBITAL MYOSITIS; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IPILIMUMAB; MAGNETIC RESONANCE IMAGING; MELANOMA; MIDDLE AGED; ORBITAL MYOSITIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 85020739575     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000178     Document Type: Article

References (11)

1. Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest. 1969;48:2096-2103.
2. Miserocchi E, Cimminiello C, Mazzola M, et al. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol. 2015;50:e2-e4.
3. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
4. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin Cases Brief Rep. 2012;6:423-426.
5. Goldstein BL, Gedmintas L, Todd DJ. Drug-Associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol. 2014;66:768-769.
6. Lecouflet M, Verschoore M, Giard C, et al. Orbital myositis associated with ipilimumab. Ann Dermatol Venereol. 2013; 140:448-451.
7. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-1755.
8. Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16:589-593.
9. Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34:177-185.
10. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210-225.
11. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol. 2012;6:53-66.